AT502722B8 - Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren - Google Patents
Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren Download PDFInfo
- Publication number
- AT502722B8 AT502722B8 AT0179005A AT17902005A AT502722B8 AT 502722 B8 AT502722 B8 AT 502722B8 AT 0179005 A AT0179005 A AT 0179005A AT 17902005 A AT17902005 A AT 17902005A AT 502722 B8 AT502722 B8 AT 502722B8
- Authority
- AT
- Austria
- Prior art keywords
- interferone
- isg
- ifi
- nuclear receptors
- induced gene
- Prior art date
Links
- 108020005497 Nuclear hormone receptor Proteins 0.000 title 1
- 102000006255 nuclear receptors Human genes 0.000 title 1
- 108020004017 nuclear receptors Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000002103 transcriptional effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0179005A AT502722B8 (de) | 2005-10-31 | 2005-10-31 | Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren |
| PCT/AT2006/000448 WO2007051218A2 (de) | 2005-10-31 | 2006-10-31 | Verfahren unter verwendung von humanem oder mäuse-isg12 zur entwicklung und herstellung von medikamenten sowie von single-nucleotide-polymorphismus im isg12-gen zu diagnosezwecken |
| US12/092,189 US20080313751A1 (en) | 2005-10-31 | 2006-10-31 | Method by Using Human or Mice-Isg12 to Develop and Prepare Drugs and Single Nucleotide Polymorphism in the Isg12 Gene for Diagnostic Use |
| EP06804375A EP1945805A2 (de) | 2005-10-31 | 2006-10-31 | Verfahren unter verwendung von humanem oder mäuse-isg12 zur entwicklung und herstellung von medikamenten sowie von single-nucleotide-polymorphismus im isg12-gen zu diagnosezwecken |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0179005A AT502722B8 (de) | 2005-10-31 | 2005-10-31 | Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AT502722A1 AT502722A1 (de) | 2007-05-15 |
| AT502722B1 AT502722B1 (de) | 2009-07-15 |
| AT502722B8 true AT502722B8 (de) | 2009-08-15 |
Family
ID=38006218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT0179005A AT502722B8 (de) | 2005-10-31 | 2005-10-31 | Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080313751A1 (de) |
| EP (1) | EP1945805A2 (de) |
| AT (1) | AT502722B8 (de) |
| WO (1) | WO2007051218A2 (de) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060141455A1 (en) * | 2002-01-08 | 2006-06-29 | Rhonda Hansen | Gene products differentially expressed in cancerous breast cells and their methods of use |
| WO2005000087A2 (en) * | 2003-06-03 | 2005-01-06 | Chiron Corporation | Gene products differentially expressed in cancerous colon cells and their methods of use ii |
| US20020137081A1 (en) * | 2001-01-08 | 2002-09-26 | Olga Bandman | Genes differentially expressed in vascular tissue activation |
| US6681543B2 (en) * | 2001-03-28 | 2004-01-27 | Toyoda Gosei Co., Ltd. | Vehicle molding and method for attaching the vehicle molding |
| WO2004011618A2 (en) * | 2002-07-29 | 2004-02-05 | Hmgene, Inc. | Methods of identifying adipocyte specific genes, the genes identified, and their uses |
| JP2006514823A (ja) * | 2002-08-20 | 2006-05-18 | ミレニアム ファーマスーティカルズ インク | 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法 |
| US20050009067A1 (en) * | 2003-05-19 | 2005-01-13 | Craig Logsdon | Expression profile of pancreatic cancer |
| JP2005204549A (ja) * | 2004-01-21 | 2005-08-04 | Hubit Genomix Inc | C型肝炎ウイルス感染者の経過に関する遺伝子およびその利用 |
-
2005
- 2005-10-31 AT AT0179005A patent/AT502722B8/de not_active IP Right Cessation
-
2006
- 2006-10-31 WO PCT/AT2006/000448 patent/WO2007051218A2/de not_active Ceased
- 2006-10-31 EP EP06804375A patent/EP1945805A2/de not_active Withdrawn
- 2006-10-31 US US12/092,189 patent/US20080313751A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007051218A3 (de) | 2007-09-20 |
| AT502722B1 (de) | 2009-07-15 |
| EP1945805A2 (de) | 2008-07-23 |
| WO2007051218A2 (de) | 2007-05-10 |
| AT502722A1 (de) | 2007-05-15 |
| US20080313751A1 (en) | 2008-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA28985B1 (fr) | Analogues de loxapine et methodes d'utilisation | |
| DE502005006470D1 (de) | Verwendung von sulfonylharnstoffen | |
| EA200901653A1 (ru) | ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC | |
| TW200716624A (en) | Compounds for modulating TRPV3 function | |
| EP1395113A4 (de) | Verwendung von follistatin zur erhöhung der muskelmasse | |
| WO2006049734A3 (en) | Quetiapine analogs and methods of use thereof | |
| EP2367974A4 (de) | Modifizierung von biomasse zur effizienten verwertung von brennstoffen | |
| BR112013005116A2 (pt) | moduladores e métodos de uso | |
| EP3846563C0 (de) | Steuerkanalsignalisierung unter verwendung von codepunkten zur anzeige des zeitplanungsmodus | |
| EP2203058A4 (de) | Verfahren und verbindungen zur modulation der cannabinoidaktivität | |
| EP2376085A4 (de) | Verbindungen und anwendungsverfahren | |
| DE602004010791D1 (de) | 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren | |
| CR10213A (es) | Moduladores de la proteína quinasa aurora | |
| DK2173730T3 (da) | Hidtil ukendte forbindelser 951: biphenyloxypropansyre som crth2-modulator og mellemprodukter | |
| BR112013014119A8 (pt) | Novos moduladores e métodos de uso | |
| DE602005002836D1 (de) | Diagnoseverfahren für erkrankungen unter verwendung von copeptin | |
| EP3989925A4 (de) | Zusammensetzung zum färben von keratinfasern und ihre verwendung | |
| DE602007008222D1 (de) | Diazepanderivate als modulatoren von chemokinrezeptoren | |
| EP2306823A4 (de) | Formulierungen von 5-fluorcytosin und ihre verwendungen | |
| BRPI0910548A2 (pt) | método e aparelho para ligar esquema de modulação codificada à quantidade de recursos. | |
| ATE510556T1 (de) | Verwendung von erythropoietin | |
| EP1814394A4 (de) | Verwendung von antioxidationsmitteln zur genmodulation | |
| DE60306716D1 (de) | Drucker mit Mitteln zur Vermeidung von Überhitzung | |
| DE60322898D1 (de) | Verwendung von isoflavonen zur förderung des schlankheitseffekts | |
| ATE448234T1 (de) | Olanzapin-analoga und verfahren zu ihrer verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EIH | Change in the person of patent owner | ||
| MM01 | Lapse because of not paying annual fees |
Effective date: 20131031 |